This is the first case to provide significant evidence that JAK inhibitor is an effective treatment for both subcutaneous and pulmonary sarcoidosis, and it is also the first case in which tofacitinib was used in a patient who has a contraindication for corticosteroid therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ced.15290 | DOI Listing |
Publication Analysis
Top Keywords
subcutaneous pulmonary
8
pulmonary sarcoidosis
8
janus kinase
4
kinase inhibitor
4
inhibitor treatment
4
treatment improved
4
improved subcutaneous
4
sarcoidosis patient
4
patient glaucoma
4
glaucoma case
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!